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ABSTRACT Intact and broad immune cell effector functions and speciﬁc individual
cytokines have been linked to HIV disease outcome, but their relative contribution
to HIV control remains unclear. We asked whether the proteome of secreted cyto-
kines and signaling factors in peripheral blood can be used to discover speciﬁc
pathways critical for host viral control. A custom glass-based microarray, able to
measure 600 plasma proteins involved in cell-to-cell communication, was used to
measure plasma protein proﬁles in 96 HIV-infected, treatment-naive individuals with
high (50,000) or low (10,000 HIV RNA copies/ml) viral loads. Univariate and re-
gression model analysis demonstrate that plasma levels of soluble interleukin-27 (IL-
27) are signiﬁcantly elevated in individuals with high plasma viremia (P  0.0001)
and are positively correlated with proviral HIV-DNA copy numbers in peripheral
blood mononuclear cells (PBMC) (Rho  0.4011; P  0.0027). Moreover, soluble IL-27
plasma levels are negatively associated with the breadth and magnitude of the total
virus-speciﬁc T-cell responses and directly with plasma levels of molecules involved
in Wnt/-catenin signaling. In addition to IL-27, gene expression levels of the speciﬁc
IL-27 receptor (IL27RA) in PBMC correlated directly with both plasma viral load
(Rho  0.3531; P  0.0218) and the proviral copy number in the peripheral blood as
an indirect measure of partial viral reservoir (Rho  0.4580; P  0.0030). These re-
sults were validated in unrelated cohorts of early infected subjects as well as sub-
jects before and after initiation of antiretroviral treatment, and they identify IL-27
and its speciﬁc receptor as a critical immune axis for the antiviral immune response
and as robust correlates of viral load and proviral reservoir size in PBMC.
IMPORTANCE The detailed knowledge of immune mechanisms that contribute to
HIV control is a prerequisite for the design of effective treatment strategies to
achieve HIV cure. Cells communicate with each other by secreting signaling proteins,
and the blood is a key conduit for transporting such factors. Investigating the com-
munication factors promoting effective immune responses and having potentially
antiviral functions against HIV using a novel focused omics approach (“communi-
come”) has the potential to signiﬁcantly improve our knowledge of effective host
immunity and accelerate the HIV cure agenda. Including 140 subjects with variable
viral loads and measuring the plasma levels of 600 soluble proteins, our data high-
light the importance of Th17 cells and Wnt/-catenin signaling in HIV control and
especially identify the IL-27/IL-27 receptor subunit alpha (IL-27RA) axis as a predictor
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of plasma viral load and proviral copy number in the peripheral blood. These data
may provide important guidance to therapeutic approaches in the HIV cure agenda.
KEYWORDS communicome, HIV, HIV replication control, IL-27 cytokine, Th17
signaling, Wnt signaling, soluble communication factors
Asmall but considerable proportion (1 to 3%) of individuals can control their HIVinfection in the absence of antiretroviral treatment (1, 2), while others progress to
full-blown AIDS within a few years after infection (3). Despite extensive cohort studies
and detailed host genetic studies, proteomics analyses, and host gene expression
proﬁling, the mechanisms that mediate this relative in vivo viral control remain poorly
understood (4–7). We put a special focus on secreted proteins that are involved in
cell-to-cell communication within and across tissues (such as growth factors, cytokines,
or chemokines) and for which the blood is a key conduit for their transport. Measuring
such soluble plasma “communicome” proﬁles has served for the prediction of early-
onset Alzheimer disease, where testing an overall small cohort for a relatively limited
set of soluble plasma factors (n  120) yielded speciﬁc proﬁles predictive of early
disease onset (8). Many of these soluble factors are essential in orchestrating an
effective host immune response, and some of them may, in the setting of viral
infections such as HIV or hepatitis C virus, also possess direct antiviral properties.
Here, we applied the communicome approach to test whether the analysis of
communication factors in the peripheral blood of HIV-infected individuals would yield
individual cytokines or cytokine proﬁles predictive of viral control. Our results identify
plasma interleukin-27 (IL-27) levels and IL-27 receptor subunit alpha (IL-27RA) expres-
sion in peripheral blood mononuclear cells (PBMC) as markers of HIV load and blood
viral reservoir size. Moreover, the differential plasma levels of IL-27 are also related, with
dysregulated plasma levels of other members of the IL-17 family and several Wnt/-
catenin signaling factors, which may explain the well-known imbalance of Th17/T-
regulatory (Treg) cells during uncontrolled chronic HIV infection.
RESULTS
Communicome proﬁles associated with HIV chronic untreated infection. In
order to test whether plasma communicome analysis of HIV-infected individuals with
different levels of viremia would yield cytokine proﬁles predictive of relative viral
control in vivo, we used custom glass-based microarrays printed with commercially
available antibodies to detect a total of 612 secreted signaling proteins (see Table S1
in the supplemental material, communicome chip). This ﬁrst analysis included plasma
samples from HIV-infected patients with low (HIV-Low; n  49) and high (HIV-High;
n  47) plasma viral loads (Table S2). Global pathway analysis highlighted several
strongly dysregulated immune pathways (Fig. 1A), among them cytokines involved in
IL-6, IL-8, IL-10, IL-17, and transforming growth factor beta (TGF-) signaling. The
dysregulated IL-17 signaling was especially strongly supported by the involvement of
additional canonical pathways that intersect with IL-17 function and by the presence of
several members of the IL-17 cytokine family (IL-17C and IL-17F) among the 80 most
differentially expressed factors (Top80) (Fig. 1B and C). Furthermore, HIV-High and
HIV-Low patients showed different expression of markers involved in the dendritic cell
maturation and global inﬂammatory process (acute-phase response, complement sys-
tem, coagulation cascade, and diapedesis) pathways (Fig. 1A to C), possibly reﬂecting
an increased immune activation due to ongoing HIV replication. The communicome
data also revealed strongly dysregulated pathways involving inhibition of metallopro-
teases, death receptors (including TNF receptors family) and Wnt/-catenin signaling
(Fig. 1A to C). Wnt/-catenin signaling was also prominently represented among the
Top80 soluble proteins (9%, including factors DKK1, WNT1, WISP2, and WIF1).
The association between IL-17 and Wnt/-catenin signaling pathways and the levels
of viremia was further validated by multivariate analyses using a recently described
approach (forward and all-subsets regression for model selection, or FARMS [9]). FARMS
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FIG 1 Communicome pattern proﬁles associated with control of HIV replication. Communicome analysis was performed in 96 HIV-infected individuals with high
(HIV-High; n  47) and low (HIV-Low; n  49) HIV plasma viral load in the absence of ART. (A) The percentage of soluble factors with signiﬁcant differential
plasma levels (P  0.05) between HIV-High and HIV-Low is shown for the most severely dysregulated canonical pathways. Elevated and reduced plasma levels
of communicome factors in HIV-infected patients with high viral loads are marked in red and green, respectively. PPAR, peroxisome proliferator-activated
receptor; MAPK, mitogen-activated protein kinase (MAPK); FGF, ﬁbroblast growth factor; VEGF, vascular endothelial growth factor; eNOS, endothelial nitric oxide
synthase; TNF, tumor necrosis factor; FXR, farnesoid X receptor; LXR, liver X receptor; VDR, vitamin D receptor; RXR, retinoid X receptor; ECM, extracellular matrix;
(Continued on next page)
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analyses revealed around 40 soluble factors for each round of execution that were
strongly associated with HIV load. Table 1 provides the best-ﬁt model for prediction of
HIV viremia (Bayesian information criterion [BIC], 103.1283; Akaike information criterion
[AIC], 9.702973), where IL-17D (also known as IL-27 and referred to here as such) as
well as Wnt inhibitory factor 1 (WIF1) were present in the model. Moreover, correlation
analyses indicated that IL-27 was the statistically most robust factor associated with
FIG 1 Legend (Continued)
MWU, Mann-Whitney U test. (B) Pie charts indicating Gene Ontology Biofunction representation of Top80 factors with signiﬁcant differences (MWU, t test, and
false discovery rate of 0.1) between HIV-High and HIV-Low. (C) Heatmap of top 80 soluble factors identiﬁed by univariate analyses that provided the most
stringent stratiﬁcation of HIV-High and HIV-Low (red color indicates higher protein plasma levels, and green indicates lower protein plasma levels). (D) IL-27
mean ﬂuorescence intensity levels (5 replicates) detected at 488-nm absorbance in communicome in HIV-Low and HIV-High groups after background
subtraction from mean foreground. (E) IL-27 relative expression levels measured in communicome in HIV-Low and HIV-High groups after Z-score normalization
of all the chip data. Mann-Whitney test was applied for group comparisons, and P values of 0.05 were considered signiﬁcant.
TABLE 1 Forward and all-subsets regression for model selection for viral load
FARMS target Estimate SE t value Pr(>|t|) Signiﬁcancea
Intercept 7.73E01 2.51E02 0.308 0.759395
ACVR2A 7.76E02 5.97E03 12.997 2.E16 ***
BMP2 6.18E01 3.59E02 17.230 2.E16 ***
BMP3 1.26E01 1.78E02 7.116 2.93E09 ***
CCL13_hu 4.51E02 3.75E03 12.022 2.E16 ***
CCL13_X 8.38E02 2.89E02 2.906 0.005339 **
CCL20 1.81E02 5.28E03 3.434 0.001163 **
CCL21 1.88E02 9.03E03 2.079 0.042505 *
CLEC11A 6.96E02 4.56E03 15.239 2.E16 ***
CNTNAP1 5.49E01 2.84E02 19.322 2.E16 ***
COL18A1 3.39E01 2.65E02 12.816 2.E16 ***
CSF1 1.11E02 3.56E03 3.133 0.002820 **
CST3 1.07E02 3.47E03 3.079 0.003287 **
CTF1 3.50E02 8.50E03 4.111 0.000138 ***
CXCL16 5.31E01 3.73E02 14.218 2.E16 ***
FGF17 4.23E02 4.06E03 10.421 1.95E14 ***
FGF3_hu 2.22E01 4.81E02 4.617 2.52E05 ***
FTL_hu 2.75E02 6.59E03 4.176 0.000111 ***
GRN_X 3.59E01 3.02E02 11.894 2.E16 ***
HCRT 6.85E02 4.42E03 15.497 2.E16 ***
ICAM2 2.76E02 3.57E03 7.732 3.00E10 ***
IL-12A 6.05E02 1.99E02 3.041 0.003665 **
IL-17D 2.49E02 5.40E03 4.615 2.54E05 ***
LTA 6.29E00 3.26E01 19.289 2.E16 ***
MMP25 5.85E01 9.19E02 6.367 4.69E08 ***
NGFR 8.52E03 4.98E03 1.710 0.093029 ·
NLGN1_hu 4.77E01 2.24E01 2.125 0.038236 *
NLGN1_X 1.19E01 4.10E02 2.896 0.005486 **
NLGN4X 1.26E01 2.50E02 5.050 5.58E06 ***
NOG_hu 9.37E01 4.56E02 20.552 2.E16 ***
NOG_X 4.50E01 1.34E01 3.356 0.001469 **
NPY_X 3.47E00 2.24E01 15.507 2.E16 ***
NRG1_hu 7.93E02 8.80E03 9.013 2.80E12 ***
SERPING1 1.02E01 8.17E03 12.533 2.E16 ***
SIGIRR 3.24E02 4.02E03 8.070 8.65E11 ***
SLC2A1 2.15E01 2.08E02 10.373 2.30E14 ***
SORL1_hu 1.08E00 1.86E01 5.796 3.82E07 ***
SPARC_hu1 5.85E02 8.72E03 6.712 1.31E08 ***
SPARC_hu2 5.92E01 8.40E02 7.044 3.84E09 ***
THBS4 2.05E01 3.93E02 5.226 2.98E06 ***
TIE1 6.15E02 8.83E03 6.960 5.22E09 ***
VEGFC 1.39E00 9.69E02 14.374 2.E16 ***
WIF1 1.74E01 1.44E02 12.070 2.E16 ***
aSigniﬁcance codes: ***, 0.001; **, 0.01; *, 0.05; ·, 0.1. Residual standard errors, 0.1958 on 53 degrees
of freedom; multiple R2, 0.9897; adjusted R2, 0.9815; F statistic, 120.9 on 42 and 53 degrees of freedom; P 
2.2E16. Residuals: minimum, 0.43703; 1st quartile, 0.08250; median, 0.00196; 3rd quartile, 0.07220;
maximum, 0.52013. AIC, 9.702973; BIC, 103.1283; Pr(|t|), proportion of t distribution greater than t
statistic.
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viral load (Rho  0.3084; P  0.0063; q  0.0376 by Spearman rank test) among the
factors identiﬁed by FARMS. Overall, these global analyses indicated that IL-17 signaling
(especially IL-27) (Fig. 1D and E) and, to a lesser extent, the Wnt/-catenin pathway are
critical pathways for HIV control during chronic infection.
IL-27 plasma levels are associated with viremia and reduced HIV-speciﬁc T-cell
responses. Given the described effects of the IL-17 cytokine family on immune
function, and IL-27 in particular, on HIV infection (10–12), we asked how plasma levels
of IL-17A, IL-17B, IL-17C, IL-17F, and IL-27 were related to HIV load and CD4 T-cell
counts. As shown in Table 2 and Fig. 2A and B, plasma levels of IL-27 showed the
strongest signiﬁcant correlations with these 2 parameters (for viral load, Rho of 0.3084
and P value of 0.0063; for CD4, Rho of 0.2798 and P value of 0.0146; Spearman rank
TABLE 2 Plasma protein levels of IL-17 family members measured in communicome
associated with clinical and virological parameters
IL-17
member
Viral load (plasma
HIV RNA copies/ml)
CD4 count
(cells/mm3)
Proviral load (HIV-
DNA copies/106
PBMCs)
Rho P value Rho P value Rho P value
IL-17A 0.2398 0.0186 0.1290 0.2105 0.0905 0.5112
IL-17B 0.2119 0.0382 0.1270 0.2175 0.1502 0.2736
IL-17C 0.2871 0.0046 0.2332 0.0222 0.1452 0.2900
IL-17D (IL-27) 0.3084 0.0063 0.2798 0.0146 0.4011 0.0027
IL-17F 0.1594 0.1209 0.1744 0.0893 0.0736 0.5933
FIG 2 IL-27 plasma levels during HIV chronic infection are associated with viral load, reservoir size, HIV-speciﬁc CTL responses, and IL-17F
plasma levels. Relative IL-27 plasma levels (x axis) are compared to either plasma HIV RNA copies per milliliter of peripheral blood (A), CD4
cell counts in the peripheral blood (B), proviral DNA levels per million of PBMC (C), the breath (D) and the magnitude (E) of T-cell responses
against the entire HIV proteome detected by IFN- ELISpot assay, or IL-17F relative plasma levels (F). All 96 subjects are represented (dark gray
circles), and HIV-High (light gray circles) and HIV-Low (open circles) individuals are shown. Spearman rank test for correlation studies was
applied, and associations were considered signiﬁcant for P values of 0.05. n.s., not signiﬁcant.
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test) among the tested IL-17 cytokines. In order to study the relationship between
relative plasma levels of IL-17 cytokines and latent reservoir in peripheral blood, proviral
DNA levels in total PBMC were measured by droplet digital PCR (ddPCR). Of note, since
latent reservoir (persistently infected cells) can be detected in blood but are also
distributed in different tissues (such as gastrointestinal tract, genital tract, and central
nervous system) (13), and since the ddPCR approach detects both integrated virus and
productively infected cells (14), measuring HIV proviral DNA copy numbers in PBMC
reﬂects only a partial latent reservoir. Still, strong associations were observed between
IL-27 plasma levels and proviral DNA levels in total PBMC (Rho  0.4011; P  0.0027;
Spearman rank test) (Fig. 2C), suggesting an important role of this cytokine in the
establishment and/or maintenance of a latent reservoir, at least in the peripheral blood.
Among the multiple proinﬂammatory effects that IL-27 exerts in vivo is the promo-
tion of T-cell proliferation, production of gamma interferon (IFN-) by CD4 T cells, and
the driving of strong cytotoxic T lymphocyte (CTL) responses (10, 12). Thus, the
relationship between the plasma levels of IL-27 and the ex vivo CTL responses against
the entire HIV proteome was assessed. This analysis showed an inverse correlation
between IL-27 levels and the total CTL breadth (measured by IFN- enzyme-linked
immunosorbent spot [ELISpot] assay; Rho  0.3126; P  0.0344; Spearman rank test)
and the total CTL magnitude (Rho  0.3859; P  0.0081; Spearman rank test) in
HIV-infected patients with high viral loads (Fig. 2D and E), indicating that the higher
plasma levels of IL-27 were associated with weaker CTL responses in this group. On the
other hand, IL-27 has well-described immune-regulatory properties, among them the
ability to repress Th17 responses, which may lead to reduced frequencies of Th17 cells
in HIV-infected subjects with high plasma viremia. Indeed, the HIV-High individuals,
who showed higher levels of IL-27 in the plasma than the HIV-Low group (Fig. 2F), also
showed an inverse correlation between IL-27 and IL-17F (one of the hallmark cytokines
of Th17 cells) (Rho  0.3525; P  0.0270; Spearman rank test). No statistically
signiﬁcant association between IL-27 or IL-17F levels was observed in HIV-Low subjects
(Fig. 2F). Overall, these data suggest that the IL-17 cytokine family, particularly IL-27,
have a profound impact on HIV reservoir in peripheral blood, viral replication, CTL
responses, and HIV disease progression, and that elevated levels of IL-27 are linked to
uncontrolled viral replication and weaker HIV-speciﬁc immune responses.
Wnt/-catenin signaling activation is associated with IL-27 plasma levels in
chronic uncontrolled HIV infection. The Wnt/-catenin pathway is centrally involved
in major physiologic cellular functions, such as proliferation, migration, and pluripo-
tency maintenance. During recent years, a direct relationship between Wnt/-catenin
signaling factors and control of viral infections, including cytomegalovirus and HIV
infection, has emerged (15–18). In line with these data, we found plasma levels of
several factors involved in the Wnt/-catenin pathway (including activators [e.g., WNT1]
as well as inhibitors [e.g., WIF1]) to be differentially expressed between HIV-Low and
HIV-High individuals (Fig. 3A and B). In addition, the Wnt/-catenin activating factor
WNT1 was inversely associated with viral load (Rho  0.2775; P  0.0062; Spearman
rank test; data not shown) and also correlated inversely with IL-17A in patients with
high plasma viremia (Rho  0.4239; P  0.0030; Spearman rank test) (Fig. 3C). These
data suggest that reduced levels of IL-17A (indirect measure of Th17 responses) in
HIV-High subjects are under Wnt/-catenin regulation. This is further corroborated by
our ﬁnding that plasma levels of IL-27 and WNT1 were directly correlated in both
HIV-Low (Rho  0.3259; P  0.0223; Spearman rank test) (Fig. 3D) and in HIV-High
groups (Rho 0.3619; P 0.0125; Spearman rank test) (Fig. 3D). These observations are
in line with recent reports showing that Wnt/-catenin signaling promotes the expres-
sion of IL-27 in dendritic cells and that secreted IL-27 suppresses Th17 responses (19).
Taken together, these communicome data establish a relationship between the Wnt/
-catenin and IL-17 family signaling pathways with the in vivo control of HIV, with IL-27
potentially acting as the interconnecting factor between these pathways.
Lower plasma levels of IL-27 are linked to reduced IL27RA expression in PBMC
of HIV controllers. To validate the signals emerging from the communicome analyses
Ruiz-Riol et al. Journal of Virology
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in the above-described 96 individuals, we assessed plasma levels of IL-17 family
cytokines in unrelated cohorts, including seronegative subjects, chronically infected
individuals (before and after combined antiretroviral treatment [cART] initiation), and
controller subjects (including viremic [VC] and elite [EC] HIV controllers) (Fig. 4; Table S3
and Fig. S1). Although the group sizes were considerably smaller than those in the
initial cohort, signiﬁcantly lower IL-27 plasma levels were seen in elite controller
individuals compared to chronically untreated infected subjects with high viremia (Fig.
4A), conﬁrming the data obtained in the communicome analyses. Longitudinal analyses
of individuals who were tested a median of 12 months before and after initiation of
cART did not show any signiﬁcant reduction of IL-27 plasma levels upon treatment
(data not shown). This suggests that reducing viremia by cART does not readily restore
a low IL-27 proﬁle, at least not within 12 months on suppressive treatment. No
differences in IL-17A and IL-17F plasma levels were detected between the various
groups (Fig. S1), suggesting that among the different IL-17 family members, IL-27 plays
the most prominent role in the outcome of HIV infection.
IL-27 binds to its heterodimeric receptor, composed of the IL-27 receptor  chain
(IL-27RA) and the gp130 chain, which is shared with other heterodimeric receptors for
other cytokines, particularly IL-6 (10). Since IL-27RA mediates speciﬁcity to IL-27 bind-
ing, the expression level of this subunit was measured in RNA isolated from total PBMC
FIG 3 Plasma levels of Wnt/-catenin pathway proteins are associated with IL-17 signaling in chronic HIV
infection. (A) Differential relative plasma levels of Wnt/-catenin inhibitor 1 (WIF1) and activator (WNT1)
factors between HIV-High (light gray circles) and HIV-Low (open circles) detected in the communicome
screens. (B) Inverse relationship between relative plasma levels of WNT1 (x axis) and WIF1 (y axis) across
all individuals. (C) Inverse correlation between relative plasma levels of WNT1 (x axis) and IL-17A (y axis)
in HIV-High (light gray circles) and HIV-Low (open circles) subjects. (D) Positive association between
relative plasma levels of WNT1 (x axis) and IL-27 (y axis) detected in HIV-High (light gray circles) and
HIV-Low (open circles) subjects. The Mann-Whitney test was applied for group comparisons and the
Spearman rank test for correlation analyses. P values of 0.05 were considered signiﬁcant.
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from HIV-seronegative individuals, chronically infected subjects (with and without
cART), and controllers. Compared to HIV-uninfected subjects, HIV-infected individuals
with uncontrolled and untreated HIV infection showed an increased expression of
IL27RA (Fig. 4B), while in HIV controllers (viremic and elite controllers) its expression was
low and at levels seen in HIV-seronegative individuals (Fig. 4B). Of note, among HIV
controllers, viremic subjects (2,000 copies/ml) and elite controllers (50 copies/ml)
showed equally low IL27RA expression (Fig. 4B). Similarly, separating viremic noncon-
trollers into groups that did or did not receive treatment did not reveal any differences
in expression of IL27RA (Fig. 4C). More importantly, IL27RA expression levels across all
groups (controllers and noncontrollers as well as HIV-negative individuals) were directly
correlated with the concentration of IL-27 cytokine in the plasma (Rho  0.3024; P 
0.0367; Spearman rank test) (Fig. 4D), establishing a link between coordinated IL-27
cytokine, IL27RA expression, and HIV control. Accordingly, and as seen with IL-27,
IL27RA also positively correlated with viral load (Rho  0.3531; P  0.0218; Spearman
rank test) and proviral DNA levels in total PBMC (Rho  0.4580; P  0.0017; Spearman
rank test) (Fig. 4E and F). Taken together, these data indicate that reduced levels of
IL-27 and IL27RA serve as markers of HIV load and proviral DNA levels in total PBMC.
DISCUSSION
A better understanding of the mechanisms by which host immunity contributes to
HIV control in the absence of antiretroviral treatment will be needed to guide future
immune-based interventions, especially in the therapeutic vaccination setting. To date,
the ﬁne speciﬁcity of HIV-speciﬁc CD8 T cells, the maintenance of their polyfunction-
FIG 4 Low IL-27/IL27RA plasma levels during HIV chronic infection are associated with viral control. (A) Differential
plasma levels of IL-27 detected by ELISA (picograms/milliliter) are shown for samples from validation cohorts,
including HIV seronegatives (SeroNeg) (n 6), chronically infected, viremic, untreated HIV-infected individuals (Chr.
Untreated) (n  6), HIV viremic controller subjects (VC; n  11), and HIV elite controller patients (EC; n  12). (B)
HIV seronegatives (n  6), chronically infected, viremic, untreated HIV-infected individuals (n  6), HIV viremic
controller subjects (VC; n 11), and HIV elite controller patients (EC; n 12). (C) Relative expression levels of IL27RA
detected in PBMC by RT-PCR in chronically viremic infected subjects. Untreated, n  6; treated, n  5. (D to F)
Correlation between IL27RA gene expression in PBMC (x axis) and plasma levels of IL-27 (y axis) (D), plasma viral
loads (E), and proviral DNA copy number in total PBMC (F) in validation cohorts. The Mann-Whitney test was
applied for groups comparisons and Spearman rank test for correlation studies. P values of 0.05 were considered
signiﬁcant.
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ality, and the ability of virus-speciﬁc CD8 T cells to suppress in vitro viral replication
has been most consistently associated with reduced viral loads in chronic HIV infection
(20–23). Here, we applied, for the ﬁrst time, an innovative communicome approach that
was initially utilized to predict early onset of Alzheimer disease (8) to identify potential
soluble biomarkers involved in cellular communication that are associated with HIV
control. Our data show that elevated levels of IL-27 are associated with higher viral load
and increased size of the viral reservoir, and that these effects may be mediated by a
dysregulated Wnt/-catenin signaling pathway.
A particularity of the present study was the inclusion of individuals with high or low
viral loads in the initial communicome screens rather than focusing on elite or low-
viremia controllers. This allowed us to avoid bias toward host genetics, which are often
skewed in controller cohorts, and to identify signals that are reﬂective of a larger
proportion of the HIV-infected population than the small subset of (elite) controllers
(24, 25). Still, the subsequent replication of the observed results in unrelated cohorts,
including elite controllers, validated the chosen approach and identify IL-27 and its
receptor IL27RA as possibly critical factors in host defense and immunopathology of HIV
infection.
IL-27 is a highly pleiotropic cytokine with immune-regulatory and antiviral capabil-
ities. It belongs to the IL-6/IL-12 cytokine family (10, 11) and is composed of the
Epstein-Barr virus-induced gene 3 (Ebi3) product and the IL-27p28 chain. Its receptor is
composed of gp130 and the IL-27 receptor  chain (IL-27RA; also known as WSX1 or
TCCR). From its discovery, IL-27 was seen as a proinﬂammatory cytokine due to its
ability to suppress both Th2 responses and Foxp3 Treg differentiation, expanding Th1
cells, and promoting T-cell proliferation and CTL responses (10, 12). Our data do not
support such an effect stimulating T-cell responses, as we observed an inverse associ-
ation between the plasma levels of IL-27 and the magnitude and breadth of HIV-speciﬁc
CTL responses, at least in those subjects with high viral loads. It thus appears that at
least in this context, IL-27 does not promote the expansion of functional, HIV-speciﬁc
CTL responses.
Since IL-27 also exerts immunosuppressive effects by inhibiting the development of
Th17 cells and by inducing IL-10-producing Tr1 (Treg1 cells) (12), we also assessed the
association of IL-27 plasma levels with IL-17A and IL-17F. The inverse correlation
between IL-27 and IL-17F observed here and the reportedly higher percentages of Th17
cells in peripheral blood of HIV elite controllers suggest that IL-27 acts as a key
repressor of Th1/Th17-like responses in uncontrolled HIV infection (26, 27). Evidently,
determining cytokine plasma levels is an indirect measure of Th17 responses, and our
data interpretation is further complicated by the pleiotropic effects of IL-27 and its use
of shared coreceptors, e.g., the gp130/IL6ST molecule (28). Nevertheless, as uncon-
trolled HIV infection is characterized by low levels of Th17 cells, our data are compatible
with a scenario where low levels of IL-27 and its receptor favor increased Th17 activity
and improved viral control (29).
Our data also indicate an involvement of theWnt/-catenin pathway in the observed
association between low IL-27 and relative viral control. This is in line with data that
show the Wnt/-catenin pathway is essential for normal T-cell development and that
IL-27 suppresses Th17 differentiation (19). As such, IL-27 could impact Treg differenti-
ation by acting on the Wnt/-catenin pathway, thereby contributing to the well-known
imbalance between Tregs and Th17 cells during HIV disease progression (26, 27, 30).
However, in in vitro assays, IL-27 has also been linked with antiviral effects (11, 31), since
the addition of exogenous IL-27 to primary cell cultures has been shown to decrease
HIV-1 replication in a number of cell types, including PBMC, CD4 T cells, macrophages,
and dendritic cells. As we observed a positive association between IL-27/IL27RA ex-
pression with plasma viral load and, even more pronounced, with proviral DNA levels,
our data suggest that the in vitro analyses do not fully replicate the situation in vivo.
One possibility that accounts for this inconsistency is that IL-27 secretion and absorp-
tion mechanisms are not the same in the peripheral blood and plasma from HIV-
infected patients as those produced during in vitro experiments using primary cell
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cultures from healthy donors in the presence of exogenous IL-27. Moreover, IL-27
plasma levels are a reﬂection of different cell sources and tissues where other cytokines
coexist, including some that share the gp130 subunit of the IL-27 receptor (such as IL-6,
IL-11, oncostatin M [OSM], ciliary neurotrophic factor [CNTF], cardiotrophin-1 [CT-1],
and leukemia inhibitory factor [LIF]) that may compete for binding with this receptor
subunit, as described, for instance, for IL-6 trans-signaling (28, 32). In particular, the
effects of dysregulated Wnt/-catenin signaling on the self-renewal of CD4 T-cell
populations and maintenance of HIV reservoir by homoeostatic proliferation will need
to be assessed in the context of IL-27/IL-27RA expression proﬁles (16–18, 33, 34).
Overall, the application of a communicome approach to plasma samples from
HIV-infected individuals demonstrates the potential of such focused proteomics anal-
yses for the identiﬁcation of new molecules associated with control/noncontrol of HIV
infection. Importantly, however, our data also add to a better understanding of
immune-regulatory alterations in this highly immunogenic, persistent viral infection.
The observation that both IL-27 receptor and ligand were differentially associated with
viral load and proviral levels in PBMC also highlights the need for future therapeutic
intervention strategies to carefully evaluate whether strategies such as immune check-
point inhibitors need to be directed against more than a single target molecule.
MATERIALS AND METHODS
Patients and samples. HIV-seropositive subjects (n  96) were recruited at the Hospital Germans
Trias i Pujol, (Badalona, Spain) and the IMPACTA clinics in Lima (Peru) and used for communicome
analyses. HIV low-viremia subjects (HIV-Low; n  49) were deﬁned as individuals with viral loads of
10,000 HIV RNA copies/ml (range, 25 to 9,990; median, 530) in the absence of antiretroviral treatment;
HIV high-viremia individuals (HIV-High; n 47) were untreated subjects with50,000 HIV RNA copies/ml
(range, 50,295 to 1,200,000; median, 105,520) (see Table S2 in the supplemental material). CD4 counts in
the HIV-Low groups ranged from 289 to 1,343 cells/mm3 (median, 657 cells/mm3) and in HIV-High group
from 11 to 726 cells/mm3 (median, 283 cells/mm3) (P  0.0001 by Mann-Whitney test). Additional
unrelated cohorts were used for downstream validation of identiﬁed signals, including seronegative
(n  8) subjects, individuals with samples obtained in the chronic phase of HIV infection (n  12), and
subjects sampled pre-cART administration (untreated; median of 70 days before treatment initiation;
n  6) and post-cART initiation (treated; median of 362 days after treatment start; n  6) (Table S3). In
addition, samples from a chronically infected controller cohort (C; n  23), including viremic (VC; n  11;
viral loads of 2,000 copies/ml) and elite controllers (EC; n  12; undetectable viral loads; 50
copies/ml), were included (Table S3). The study was approved by the Comitè Ètic d’Investigació Clínica
of Hospital Germans Trias i Pujol (CEIC EO-12-042), and all participants provided written informed
consent. Plasma samples were used and processed for proteomic studies (communicome and enzyme-
linked immunosorbent assay [ELISA] determinations) as described below. For molecular assays, RNA and
DNA were extracted from PBMC.
Communicome analyses. Communicome analyses were carried out using a custom-designed chip
that allowed for the detection and quantiﬁcation of600 individual proteins (Table S1). Multiple speciﬁc
monoclonal or polyclonal antibodies for each protein were printed in triplicate on SuperEpoxy glass
slides using a custom-built robotic microarrayer ﬁtted with 16 SMP4B pins as previously described (8).
The slides were dried overnight, vacuum sealed, and stored at 20°C until use. Plasma samples were
platelet and lipid reduced by centrifugation and dialyzed (96-well DispoDialyzer with a 5-kDa molecular
size cutoff) at 4°C to yield a maximally pure plasma protein fraction. Plasma proteins were subsequently
N-terminally biotinylated, and the individual samples were incubated overnight with blocked antibody
arrays at 4°C. Finally, the arrays were washed extensively and the captured proteins detected with
streptavidin-Alexa 555 on an InnoScan 700 scanner. For data analysis, raw data were background
subtracted and normalized using Cluster analysis, and the normalized values were Z scored [z  (x 
)/]. Differences in the set of samples were analyzed by applying t test, Mann Whitney test, and the SAM
(Signiﬁcance Analysis Microarrays) 3.00 algorithm, which assigns a score to each molecule on the basis
of multicomparison analyses of expression changes and indicates signiﬁcance by q value. Molecules with
a signiﬁcance level above 95% (P value of 0.05) and a conservative false discovery rate below 10% (q
value of 0.1) were included in further analyses.
Network and array analyses. The analysis of molecule interactions was performed using Ingenuity
Pathway Analysis software (IPA; Ingenuity Systems; www.ingenuity.com), highlighting networks and
canonical pathways differentially affected by high and low HIV plasma viremia. Protein-protein interac-
tions and pathway analyses were further supported by including Kyoto Encyclopedia of Genes and
Genomes (KEGG; www.genome.ad.jp/kegg), BioCarta, GeneMania (www.genemania.org/), and PubMed
literature searches. Heatmaps and hierarchical clustering were performed using Bioconductor software
and statistical programming language R (www.r-project.org) (35, 36).
Cytokine determination by ELISA. Legend Max human ELISA kits (BioLegend) were used for the
quantiﬁcation of IL-27 (IL-17D), IL-17A, and IL-17F in plasma samples by following the manufacturer’s
procedure. In brief, after antibody coating, plates were washed and standards (duplicates) and samples
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(triplicates) were added and incubated during 2 h while shaking. After subsequent washing, human
cytokine detection antibodies were added and incubated for 1 h while shaking. Avidin-horseradish
peroxidase solution and substrate solution were then sequentially added and incubated for 30 and 15
min, respectively. Finally, stop solution was added and the absorbance at 450 nm determined (absor-
bance at 570 nm is also measured for background subtraction). For cytokine quantiﬁcation, a
4-parameter logistic nonlinear regression model was applied, and the absorbance median of 3 replicates
was used for quantiﬁcation.
Measurements of cytotoxic host immune responses to HIV. T-cell immunity to HIV was assessed
in puriﬁed PBMC by ELISpot assay (1  106 PBMC/well) using an overlapping peptide (OLP) set of 410
OLP as described previously (37). In brief, 96-well ELISpot plates (Millipore) were coated with mouse
anti-human IFN- antibody 1-D1k (Mabtech) and incubated overnight. The next day, plates were washed
six times with phosphate-buffered saline (PBS), and PBMC were added at 100,000 cells/well along with
peptide at a ﬁnal concentration of 2 g/ml. After incubation for 16 h at 37°C in 5% CO2, plates were
washed 6 times with PBS and the mouse anti-human IFN--biotinylated 7-B6-1 (Mabtech) was added for
1 h at room temperature. After washing, streptavidin alkaline phosphatase (Mabtech) was added for 1 h
at room temperature. Spots were visualized by adding 5-bromo-4-chloro-3-indolylphosphate and ni-
troblue tetrazolium (Bio-Rad) for 5 to 10 min. Culture medium alone and phytohemagglutinin P (PHA-P)
(10 g/ml) served as negative and positive controls, respectively. Spots were counted on an automated
CTL ELISpot assay reader. The breadth (number of reactive OLP) and total magnitude (median number
of spot-forming cells [SFC] per 106 PBMC for all positive responses) were recorded.
Total HIV-1 DNA quantiﬁcation. Total HIV-1 DNA was quantiﬁed in PBMC lysates by droplet digital
PCR (ddPCR) in duplicate as described previously (38). Brieﬂy, two different primer/probe sets annealing
to the 5= long terminal repeat and Gag regions, respectively, were used to circumvent sequence
mismatch in the patients’ proviruses, and the RPP30 housekeeping gene was quantiﬁed in parallel to
normalize sample input. Raw ddPCR data were analyzed using the QX100 droplet reader and QuantaSoft
v.1.6 software (Bio-Rad).
Real-time PCR. Frozen PBMC were thawed and cell pellets conserved in RNAprotect cell reagent
(Qiagen) for RNA extraction (RNeasy Plus minikit; Qiagen) and retrotranscription (SuperScript III ﬁrst-
strand synthesis supermix). The cDNA was used for reverse transcription-PCR using TaqMan gene
expression assays for detection of IL27RA (Hs00945029_m1) and TBP (Hs99999910_m1), all from Applied
Biosystems, with a LightCycler (Roche). The relative expression was calculated as 2ΔCT (where CT is the
median threshold cycle from 3 replicates).
Statistical analysis. Univariate analyses were performed using GraphPad Prism, version 5. For
comparisons between patient groups, nonparametric Mann-Whitney and Wilcoxon matched-pair tests
were applied as indicated. Spearman test was applied for correlation analyses. For all analyses, P values
of 0.05 were considered statistically signiﬁcant. Forward and all-subsets regression for model
selection (FARMS) analysis was applied to deﬁne a predictive model for viral load. FARMS is a novel
approach initially designed to identify the impact of HLA genetic diversity on HIV loads in extensive
cohorts of HIV-infected individuals (9). The method combines forward and all-subsets regression for
model selection and can be user adjusted for most input variables and output parameters. FARMS
is generally faster than other comparable, commonly used approaches and requires less computa-
tional infrastructure (9).
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